STOCK PURCHASE AGREEMENT Dated as of February 13, 2007 by and among HALOZYME THERAPEUTICS, INC. and BAXTER INTERNATIONAL INC.Stock Purchase Agreement • February 20th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of February 13, 2007, is entered into by and between Halozyme Therapeutics, Inc., a Nevada corporation (the “Company”), and Baxter International Inc., a Delaware company (the “Purchaser”), for the purchase and sale of 2,070,394 shares of the Company’s Common Stock, par value $.001 per share (the “Shares”).
AMENDED AND RESTATED DEVELOPMENT AND SUPPLY AGREEMENT (Hylenex)Development and Supply Agreement • February 20th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED DEVELOPMENT AND SUPPLY AGREEMENT (this “Agreement”) dated as of February 13, 2007 (the “Restatement Date”), is entered into between BAXTER HEALTHCARE CORPORATION, a Delaware corporation, with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633, USA, and BAXTER HEALTHCARE S.A., a Swiss corporation, with its principal place of business at Hertistrasse 2, 8304 Wallisellen, Switzerland (together with its Affiliates, collectively, “Baxter”), on the one hand, and HALOZYME, INC., a corporation existing under the laws of the State of California, with its principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121, USA (“Halozyme”), on the other hand.
AMENDED AND RESTATED EXCLUSIVE DISTRIBUTION AGREEMENT (Hylenex)Exclusive Distribution Agreement • February 20th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIS AMENDED AND RESTATED EXCLUSIVE DISTRIBUTION AGREEMENT (this “Agreement”) dated as of February 13, 2007 (the “Restatement Date”), is entered into between BAXTER HEALTHCARE CORPORATION, a Delaware corporation, with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633, USA, and BAXTER HEALTHCARE S.A., a Swiss corporation, with its principal place of business at Hertistrasse 2, 8304 Wallisellen, Switzerland (together with its Affiliates, collectively, “Baxter”), on the one hand, and HALOZYME, INC., a corporation existing under the laws of the State of California, with its principal place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121, USA (“Halozyme”), on the other hand.
ENHANZE™ LICENSE AND COLLABORATION AGREEMENT (Generic Drugs)Enhanze™ License and Collaboration Agreement • February 20th, 2007 • Halozyme Therapeutics Inc • Biological products, (no disgnostic substances) • California
THIS ENHANZE LICENSE AND COLLABORATION AGREEMENT (this “Agreement”), effective as of February 13, 2007 (the “Effective Date”) is entered into between HALOZYME, INC., a California corporation (“Halozyme”), having a place of business at 11588 Sorrento Valley Road, Suite 17, San Diego, California 92121, USA, on the one hand, and BAXTER HEALTHCARE CORPORATION, a Delaware corporation, with its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015-4633, USA, and BAXTER HEALTHCARE S.A., a Swiss corporation, with its principal place of business at Hertistrasse 2, 8304 Wallisellen, Switzerland (together with its Affiliates, collectively, “Baxter”), on the other hand, with respect to the following facts:
